![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25945-25952, September 3, 1999
-Protein Fibrillogenesis
,
,
,
,
§,
, and
¶
From the
Center for Neurologic Diseases, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts
02115 and the § Department of Physics and Center for
Material Science and Engineering, Massachusetts Institute of
Technology, Cambridge, Massachusetts 02139
| |
ABSTRACT |
|---|
|
|
|---|
Alzheimer's disease is characterized by
extensive cerebral amyloid deposition. Amyloid deposits associated with
damaged neuropil and blood vessels contain abundant fibrils formed by
the amyloid Alzheimer's disease
(AD)1 is a progressive
neurodegenerative disorder defined histologically by the formation in
the brain of intracellular neurofibrillary tangles and extracellular
amyloid deposits (1). Particular attention has been focused on the role
that the amyloid Rigorous biophysical studies of fibrillogenesis require well
characterized, homogeneous starting peptide preparations, free of
pre-existing fibrillar material, particulates, or other types of fibril
seeds. In prior studies, synthetic A Chemicals and Reagents--
Chemicals were obtained from Sigma
and were of the highest purity available. Water was double-distilled
and deionized using a Milli-Q system (Millipore Corp., Bedford, MA).
Tissue culture components were obtained from Life Technologies, Inc.
(Grand Island, NY).
Peptides--
A Size Exclusion Chromatography (SEC) System--
A Superdex 75 HR
10/30 column (Amersham Pharmacia Biotech, Piscataway, NJ) was attached
either to a Waters 650 Advanced Protein Purification system, consisting
of a Waters 650 controller and pump, a Rheodyne 9125 injector, a Waters
484 tunable absorbance detector, and a Waters 745 data module, or to a
Beckman 110B solvent delivery system module 406 and System Gold
detector module 166.
Isolation of Low Molecular Weight A Isolation of Protofibrils--
Protofibrils were prepared
essentially as described (26). Briefly, 400 µg of A Electron Microscopy--
Samples were prepared for electron
microscopy (EM) using both negative contrast and rotary shadowing
techniques. Preparation of samples for negative contrast was performed
as described (26). Briefly, sample was applied to a carbon-coated
Formvar grid, fixed with a solution of glutaraldehyde, then stained
with uranyl acetate. Samples were observed using a JEOL 1200 EX
transmission electron microscope. For rotary shadowing, casts of
samples were prepared essentially as described (30). 100-µl aliquots
of protofibril fractions were first diluted in 5 mM
imidazole, 50 mM NaCl, to ~1 ml and then diluted with 2 volumes of freshly distilled glycerol. The resulting solution was
sprayed onto newly cleaved mica sheets and rotary shadowed using a
Denton vacuum evaporator and a platinum source such that an ~1 nm
thick sheet of platinum was deposited on the mica. Following this
treatment, a thin carbon film was deposited on top of the platinum. The
replica was floated off on water and picked up with a 400-mesh copper
grid and examined using a JEOL 100 CX transmission electron microscope.
Dialysis of Radiolabeled LMW A Monitoring LMW A Preparation of Fibril Standards for Dye-binding
Experiments--
Fibrils were prepared by dissolving 800 µg of
A Congo Red Binding Assay--
Congo red binding was assessed
essentially as described by Klunk et al. (32), but with
volumes adjusted to perform the assay in a microtiter plate. Briefly,
225 µl of 20 µM Congo red in 20 mM
potassium phosphate, pH 7.4, containing 0.15 M sodium
chloride, was added to 25 µl of sample, mixed, and incubated for 30 min at room temperature. The absorbance of the resulting solutions was
then measured at 480 and 540 nm using a Molecular Devices Thermo Max
microplate reader. All samples were assessed in triplicate and the
amount of Congo red bound (Cb) calculated using the formula Cb
(nM) = [(A540/25,295) Thioflavin T Binding Assay--
Thioflavin T (ThT) binding was
assessed as described by Naiki and Nakakuki (33). 100 µl of sample
was added to a 1-cm path length cuvette containing 800 µl of water
and 1 ml of 100 mM glycine-NaOH, pH 8.5. The reaction was
then initiated by the addition of 50 µl of 100 µM ThT
in water and the solution vortexed briefly. Fluorescence was measured
after 90, 100, 110, and 120 s. Measurements were made using a
Perkin-Elmer LS-5B Luminescence spectrometer with excitation and
emission wavelengths of 446 nm (slit width = 5 nm) and 490 nm
(slit width = 10 nm), respectively. Each sample and standard was
done in triplicate.
Circular Dichroism Spectroscopy--
Solutions of protofibrils
or LMW A Preparation of LMW A
In attempting to produce fibrils, we found that when A Neuronal Cell Cultures--
Rat primary cortical neurons were
prepared according to Hartley et al. (36), with slight
modifications. Briefly, brain cells were isolated from the neocortex of
E15-17 rat embryos and plated onto poly-L-lysine coated
96-well plates at a density of 2 × 104 cells/well in
Dulbecco's minimal essential medium containing 5% (v/v) bovine calf
serum, 10% (v/v) Ham's F-12, HEPES (20 mM), L-glutamine (2 mM), and penicillin-streptomycin
(500 units/ml and 500 µg/ml, respectively). Cultures were used 2-4
days after plating.
MTT Assay--
Cell-mediated reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was
assessed according to the method of Hansen et al. (37).
Freshly isolated protofibrils or LMW A Morphological Characterization of Protofibrils--
Previous
studies of protofibril morphology utilizing negative staining and EM
(26), or AFM (22, 27), required avid macromolecule adherence to the
sample support for their success. If certain structures were washed
away during preparation of the supports, potentially important species
would not be observed. To address this issue, and to further our
efforts at understanding the gross morphology of protofibrils, we
performed electron microscopic examination of protofibrils prepared by
rotatory shadowing. In this procedure, which involves no washing, a
thin, uniform film of sample is sprayed onto a mica support from which
shadow casts are then generated and examined. Both shadowed and
negatively stained protofibrils appeared as flexible rods of length up
to ~200 nm (Fig. 1, B and
C). However, three significant differences were observed
between the two preparations. First, the estimated diameters of the
shadowed fibrils were larger (8-14 nm compared with 4-7 nm). This was
expected due to the accretion of platinum and carbon on the fibrils.
Second, the protofibrils appeared more beaded when visualized by
rotatory shadowing. The periodicity of this "beading" was 3-6 nm.
Third, the proportion of small protofibrils (<10 nm) was higher,
suggesting that many of these structures are lost during routine
negative staining. The smallest assemblies appear as somewhat imperfect
spheres, approximately one fibril diameter in size.
Protofibrils Are in Equilibrium with LMW A Fibril Formation by Protofibrils--
The equilibria found to
exist among LMW A Tinctorial Properties of Protofibrils--
One of the
distinguishing features of amyloid is its capacity to bind the dyes
Congo red and thioflavin T, an activity dependent on the presence of
extensive arrays of
In four of the six Congo red binding experiments, samples were also
examined for their ability to bind thioflavin T. As with Congo red,
both protofibrils and fibrils, but not LMWA Secondary Structure of Protofibrils--
Numerical estimates of
the secondary structure content of protofibrils were obtained using
circular dichroism spectroscopy. Protofibrils were isolated by SEC and
examined immediately. The prominent features of the resulting spectrum
were a minimum at ~215 nm and a maximum at ~200 (Fig.
5A). The two low wavelength points of inflection are characteristic of Biological Activity of Protofibrils--
An important question is
whether protofibrils are biologically active. To answer this question,
structure-activity studies must be performed rapidly, over a time scale
of minutes to hours, before protofibrils produce fibrils. Assays
measuring cell death typically require incubation periods of days (40).
The MTT assay, in contrast, can reveal physiologic effects induced by
treatment of cells with exogenous agents after incubation times of only a few hours (23, 41-43). We thus used this assay to determine whether
protofibrils could affect the normal physiology of cultured primary rat
cortical neurons. Protofibrils were isolated by SEC and aliquots of the
protofibril peak used for the assay, for electron microscopic studies,
and for AAA. This procedure ensured that protofibril preparations of
proven morphology and known protein concentration were used. We found
that protofibrils caused a significant (p < 0.01)
reduction in the levels of reduced MTT (Fig.
6). As a positive control, preformed A An intriguing and important area of biomedical research is that of
the amyloidoses, a group of diseases caused by the fibrillogenesis and
deposition of otherwise soluble and physiologically normal proteins and
peptides (38, 39). At least 17 different molecules have been shown to
have the capacity, under appropriate conditions, to form amyloid (44).
Among these molecules, A In our initial description of protofibrils (26), temporal changes in
the levels of LMW A Additional support for a protofibril An interesting observation in our study of the temporal change in
secondary structure of A At the core, both literally and figuratively, formation of amyloid
fibrils results from mutually dependent local and global conformational
changes in A An important goal in studies of amyloid fibrillogenesis is the
correlation of structure with biological activity. In preliminary experiments, treatment of cultured cortical cells with protofibrils or
fibrils produced no detectable changes in cell number or LDH release
within a time frame (<24 h) precluding maturation of protofibrils into
fibrils.5 We therefore chose
to use the MTT assay because it has been shown to be a rapid and
sensitive indicator of A The toxic potential of A
-protein (A
). Fibrils, both in vitro and
in vivo, are neurotoxic. For this reason, substantial
effort has been expended to develop therapeutic approaches to control
A
production and amyloidogenesis. Achievement of the latter goal is
facilitated by a rigorous mechanistic understanding of the
fibrillogenesis process. Recently, we discovered a novel intermediate
in the pathway of A
fibril formation, the amyloid protofibril
(Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) J. Biol. Chem. 272, 22364-22372). We report here results of studies of the assembly,
structure, and biological activity of these polymers. We find that
protofibrils: 1) are in equilibrium with low molecular weight A
(monomeric or dimeric); 2) have a secondary structure characteristic of
amyloid fibrils; 3) appear as beaded chains in rotary shadowed
preparations examined electron microscopically; 4) give rise to mature
amyloid-like fibrils; and 5) affect the normal metabolism of cultured
neurons. The implications of these results for the development of
therapies for Alzheimer's disease and for our understanding of fibril
assembly are discussed.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-protein (A
), the primary protein constituent of
amyloid deposits, plays in development of AD. A
molecules are
fibrillogenic and exist in a number of forms in vivo (2). Among those forms found in amyloid deposits, 40 and 42 residue long
species (A
(1-40) and A
(1-42), respectively) are particularly important. Genetic studies of AD have shown that mutations in the gene
encoding the precursor of A
(the amyloid
-protein precursor (
APP) gene) (3-6), or in genes that regulate the proteolytic processing of
APP (7-9), cause AD. The phenotypic effects of these
mutations show remarkable consistency, they all result in excessive
production of A
or in an increased A
(1-42)/A
(1-40) ratio,
facilitating amyloid deposition (10, 11). In addition, specific
haplotypes and mutations in genes involved in the extracellular transport or cleavage of A
are risk factors for AD (12, 13). In vitro and in vivo studies of A
toxicity
indicate that fibrillar A
can directly kill neurons or initiate a
cascade of events leading to neuronal cell death (14-16). For this
reason, therapeutic strategies targeting A
fibrillogenesis are being
pursued actively (17-20). Unfortunately, key areas of A
fibrillogenesis are poorly understood. In particular, the
three-dimensional structure and organization of fibril subunits are
unknown, as are the steps involved in assembly of nascent, monomeric
A
first into nuclei, then into higher order oligomers and polymers.
Identification of structural intermediates in the fibrillogenesis
process and elucidation of the thermodynamics of the associated
conformational changes in, and assembly of, A
will facilitate
identification of therapeutic targets.
has been dissolved in water or
in organic solvents, then diluted directly into buffer for use
(21-24). It has been demonstrated that when synthetic A
peptides
are resuspended at neutral pH they contain a heterogeneous mixture of
different sized species (25, 26). In some cases, attempts to physically
"de-seed" stock peptide solutions have been made (21). However, in
most studies, either no precautions were taken or filtration through
0.2-µm filters, incapable of removing anything other than large
aggregates, was used. The use of these solutions complicates data
interpretation and precludes the study of the earliest phases of
fibrillogenesis in vitro. We recently demonstrated that size
exclusion chromatography (SEC) can be used to prepare homogeneous
populations of A
, termed low molecular weight A
(LMW A
), which
are composed of monomeric or dimeric A
molecules (26). Using these
preparations to study A
fibrillogenesis, we discovered and reported
the initial characterization of a new fibrillogenesis intermediate, the
amyloid protofibril (26). This intermediate was also described
independently by Harper et al. (22). Protofibrils are short,
flexible fibrils, generally 4-10 nm in diameter and up to 200 nm in
length, as measured by negative staining and electron microscopy.
Protofibrils appear transiently during A
fibrillogenesis (26, 27).
Evidence suggests that protofibrils are precursors of the longer, more
rigid, amyloid-type fibrils typically produced in vitro
using synthetic peptides (22, 26). If an analogous fibril maturation
mechanism operates in vivo, the protofibril stage could be
an important therapeutic focus. This may, in fact, be the case as
soluble oligomeric forms of A
have been isolated from human AD brain
(28). We report here results of studies which significantly extend our
knowledge of protofibril morphology, the kinetics and equilibria of
protofibril formation and disappearance, the secondary structure of
protofibrils and their LMW A
precursors, and the biological activity
of protofibrils. Our findings suggest that in developing therapies
targeting A
toxicity, consideration must be given not only to the
effects of mature, amyloid-type fibrils, but also to those of
protofibrils, and potentially, protofibril precursors.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(1-40) was synthesized and purified in our
laboratory as described (26). Peptide mass, purity, and quantity were
determined by a combination of matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry, analytical high
performance liquid chromatography, and quantitative amino acid analysis
(AAA). Purified peptides were aliquoted, lyophilized, and stored at
20 °C until used. A
(1-40) was also obtained from Bachem
(Torrance, CA) and Quality Controlled Biochemicals (Hopkington, MA).
Estimates of peptide content were provided by each manufacturer.
Iodinated A
(1-40) (125I-A
(1-40); ~2000 Ci/mmol in
35% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid) was
generously provided by Dr. Evelyn R. Stimson, University of Cincinnati
College of Medicine.
(LMW A
)--
In this
work, the term "low molecular weight A
" (LMW A
) signifies an
A
species which elutes from a SEC column as a single peak and has a
hydrodynamic radius consistent with that of either an extended monomer
or a compact dimer (determined by quasielastic light scattering
spectroscopy (QLS) to be 1-2 nm) (26). To isolate LMW A
,
A
(1-40) was dissolved at a concentration of 2 mg/ml in dimethyl
sulfoxide and sonicated in a Branson 1200 ultrasonic water bath for 10 min, after which 200 µl of this solution were injected into the SEC
column. The column was eluted with 0.05 M Tris-HCl, pH 7.4, containing 0.02% (w/v) sodium azide, at a flow rate of 0.5 ml/min.
Peptides were detected by UV absorbance at 254 nm, and 350-µl volume
fractions were collected during elution of the LMW A
peak.
Pre-dissolution of A
in either dimethyl sulfoxide or buffer gave
essentially the same results with respect to SEC and subsequent QLS and
circular dichroism spectroscopy (CD) analysis, but dimethyl sulfoxide
treatment significantly increased the recovery of peptide.
(1-40) were
dissolved in 100 µl of water, diluted with an equal volume of 0.2 M Tris-HCl, pH 7.4, containing 0.04% (w/v) sodium azide,
then incubated at room temperature for 40-60 h. The yield of
protofibrils varied among different peptide lots, but a 1-2-day
incubation period generally yielded equivalent amounts of protofibrils
and LMW A
. Following incubation, the solution was centrifuged at
16,000 × g (measured at tube bottom) for 5 min, then
~160 µl of the supernate were fractionated by SEC, as described
above. This procedure yields a symmetric peak in the void volume of the
column (Mr > 30,000 for dextrans) which contained protofibrils and a peak of LMW A
in the included volume (26). Electron microscopic examination of the assemblies in the void
peak have revealed small globular structures ~5 nm in diameter and
rods with lengths up to ~200 nm. Based on a 4-5-nm diameter rod and
a linear density of A
molecules of 0.8 nm
1 (29), the
molecular masses of these assemblies would range from ~25 to 900 kDa.
and Protofibrils--
400 µg
of A
(1-40) were dissolved in 20 µl of dimethyl sulfoxide, to
which was added 10 µl of 125I-A
(1-40). This mixture
was then diluted with 70 µl of water, 100 µl of 0.2 M
Tris-HCl, pH 7.4, containing 0.04% (w/v) sodium azide, and then
incubated at room temperature for 48-60 h. Following incubation, the
solution was centrifuged at 16,000 × g for 5 min and
160 µl of supernate fractionated by SEC, as described above. 200-µl
aliquots of the LMW A
and protofibril fractions were placed in 1-ml
sterile Spectra/Por CE DispoDialyzers (Spectrum Scientific, Laguna
Hills, CA) and dialyzed with gentle stirring at room temperature versus 20 ml of 0.05 M Tris-HCl, pH 7.4, containing 0.02% (w/v) sodium azide. In addition, other aliquots of
the SEC fractions were used for negative contrast EM, AAA, and
scintillation counting. To ensure that the 125I-A
was
accurately tracing the cold peptide, all SEC fractions were subjected
to scintillation counting and the radiotracer profile compared with the
UV chromatogram. Only samples which showed a similar distribution of
radiolabel and UV absorbance were used. In order to monitor the release
of LMW 125I-A
(1-40) from the dialysis bag, 1-ml
aliquots of dialysis buffer were removed and counted. The aliquots were
returned to the dialysis chamber after counting (normally <5 min after
their removal). At the end of the experiment, the bag was removed,
counted, and a sample of the contents taken for negative contrast EM.
and Protofibril Size by QLS--
QLS was
performed as described previously (26). Briefly, measurements were
performed at 25 °C using a Langley Ford model 1097 autocorrelator
and a Coherent argon ion laser (Model Innova 90-plus) tuned to 514 nm.
LMW A
and protofibrils were isolated as described above. To avoid
interference from dust, QLS tubes were washed in a continual flow of
eluent from a Superdex 75 column and LMW A
or protofibril material
were collected directly into these tubes by displacement (31). The
tubes were then heat-sealed and QLS monitoring begun, usually within
2-5 min of collection.
(1-40) in 200 µl of water and then diluting with an equal volume
of 0.2 M Tris-HCl, pH 7.4, containing 0.04% (w/v) sodium
azide. This solution was incubated for 5 days at 37 °C, then
thoroughly mixed, diluted with an equal volume of water, and an aliquot
examined by EM to confirm the presence of mature fibrils. The remaining
solution was serially diluted to yield concentrations of approximately 500, 250, 125, 62, 31, and 16 µg/ml in 0.05 M Tris-HCl,
pH 7.4. Standards were used immediately or stored at
20 °C until
required. The concentrations of the standards were determined by
AAA.
(A480/46,306)] × 103. The Cb
values shown were obtained after subtraction of Cb values for buffer alone.
isolated by SEC were placed into 1-mm path length quartz
cuvettes (Hellma, Forest Hills, NY) and spectra obtained from
~195-250 nm at room temperature using an Aviv 62A DS
spectropolarimeter. Raw data were manipulated by smoothing and
subtraction of buffer spectra, according to the manufacturer's
instructions. Deconvolution of the resulting spectra was achieved using
the program CDANAL (34) and the Brahms and Brahms reference library
(35). The relative amounts of random coil,
-helix,
-sheet, and
-turn in each sample were determined from the normalized
contribution of each secondary structure element function to the
observed spectrum following curve fitting.
, Protofibrils, and Fibrils for Biological
Activity Studies--
LMW A
and protofibrils were prepared by SEC.
Briefly, 1 mg of peptide was dissolved in 250 µl of water containing
0.01% (v/v) phenol red, diluted with an equal volume of 0.2 M Tris-HCl, pH 7.4, then incubated at room temperature for
2 days. Solutions were then centrifuged at 16,000 × g
for 5 min and 400-440 µl of the supernate fractionated on a Superdex
75 column eluted with 5 mM Tris-HCl, pH 7.4, 70 mM NaCl, at 0.5 ml/min. The elution solvent was chosen
empirically after preliminary experiments showed that 0.05 M Tris buffer was toxic to cultured neurons and that LMW
A
and protofibril yields were unacceptably low in the absence of
salt. The Tris/NaCl system produced chromatograms indistinguishable from those seen using 0.05 M Tris-HCl, pH 7.4. In addition,
the morphology and hydrodynamic radii of protofibrils prepared by this
method were essentially the same as those obtained using 0.05 M Tris buffer. Peptides were detected by UV absorbance at 254 nm and 450-µl fractions were collected during elution of the LMW
A
and protofibril peaks. Fractions used for studies of biological activity were also subjected to AAA and EM.
(1-40) (from
a variety of sources) was dissolved at >1 mg/ml in water, it produced
a solution whose pH (<3) could not be adjusted properly with 5 mM Tris buffer. To overcome this problem and facilitate monitoring of the pH under sterile conditions, peptide was suspended initially at ~3.2 mg/ml in 1 mM NaOH, containing 0.01%
(v/v) phenol red. 10 mM NaOH then was added at the
empirically determined ratio of 200 µl/mg of peptide. This ratio
varied slightly among different peptide lots. Finally, the solution was
diluted sequentially with 100 mM Tris-HCl, pH 7.4, containing 1.4 M NaCl, and water to give a concentration of
~1.6 mg/ml A
(1-40) in 5 mM Tris-HCl, pH 7.4, containing 70 mM NaCl. These solutions were incubated for 2 days at 37 °C, and then used. This procedure consistently produced solutions of amyloid fibrils which could be sedimented readily by brief
centrifugation (16,000 × g, 5 min) and which were
indistinguishable from those formed by incubation in 50 mM
Tris-HCl, pH 7.4.
fractions were mixed with
concentrated stock solutions of individual tissue culture components to
produce a final solution containing 10 mM glucose, 500 units/ml penicillin, 500 µg/ml streptomycin, 20 mM HEPES,
and 26 mM NaCO3, all in 1 × minimal
essential medium. Peptide concentrations were determined prior to this
supplementation. Fibril standards were prepared in a similar fashion to
yield nominal final peptide concentrations of 5, 10, and 15 µM. Cells were incubated either in 50 µl of medium
without A
or in 50 µl containing fibrillar A
, protofibrils, or
LMW A
. After 2 h, 10 µl of 2.5 mg/ml MTT was added to each
well and the incubation continued for a further 3 h. Cells were
then solubilized in 200 µl of 20% (w/v) SDS in 50% (v/v)
N,N'-dimethylformamide, 25 mM HCl, 2% (v/v)
glacial acetic acid, pH 4.7, by overnight incubation at 37 °C.
Levels of reduced MTT were determined by measuring the difference in absorbance at 595 and 650 nm using a Molecular Devices Thermo Max
microplate reader. The effects of treatments were compared with
controls by using the one-way analysis of variance Tukey test. No
reduction of MTT was observed in fibril controls (even at a
concentration of ~30 µM) in the absence of cells.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (145K):
[in a new window]
Fig. 1.
Morphology of A
fibrils and protofibrils. Fibrils and protofibrils were
prepared from A
(1-40) and examined by transmission EM.
A, negatively stained fibrils; B, negatively
stained protofibrils; and C, rotatory shadowed protofibrils.
Plate C is a composite of two regions of the same grid. Scale
bars are 100 nm. See text for methods.
--
As a first step
toward elucidating the structural and kinetic relationships among LMW
A
and its assemblies, we asked whether protofibril formation was an
irreversible process or whether an equilibrium existed between
protofibrils and LMW A
. To do so, radiolabeled protofibrils were
isolated by SEC, immediately placed in dialysis bags of 8000 molecular
weight cut off, then aliquots of the reservoir removed periodically for
counting. Dialysis bags of 8,000 molecular weigh cut off retain >90%
of a test solute of molecular weight 8,000 after a 17-h dialysis
period. A
monomers thus are not retained. The dialysis rate for A
dimers is unknown, but would depend on the shape and hydrated volume of
these molecules. However, based simply on dimer molecular weight
(8,662), release would likely be limited. Representative results from a
series of seven experiments are illustrated in Fig.
2. Diffusion of LMW A
into the
dialysis reservoir was rapid and reproducible, with ~90% of the
total counts passing out of the sac within 72 h. The exponential
curve shape reflects a simple dialysis process in which free diffusion
of solute through the dialysis membrane occurs. A
release was also
observed from protofibrils, however, it was significantly lower and
more variable, with between 18 and 41% of the total counts found in
the reservoir after 96 h. In addition, the sigmoidal shape of the
release function is consistent with a process in which A
must first
dissociate from protofibrils before diffusing through the dialysis
membrane. The plateauing of the curve at a low level of A
release
shows that a significant portion of the A
present in the dialysis
bag is unable to diffuse out. Interestingly, in three of seven
experiments, electron microscopic studies revealed typical fibrils (as
in Fig. 1A) in the dialysis bags after 96 h (data not
shown). Protofibrils thus appear to be in equilibrium with LMW A
and
to give rise to fibrils, from which dissociation of A
does not
readily occur.

View larger version (14K):
[in a new window]
Fig. 2.
Protofibrils are in equilibrium with LMW
A
. Radiolabeled protofibrils and LMW A
were isolated by SEC and placed in separate dialysis bags (8,000 molecular weight cutoff) which were then incubated at room temperature
in separate reservoirs. Periodically, samples from the reservoirs were
counted to determine the amount of radiolabeled A
diffusing out of
the bags. The results shown were typical of the total of seven
performed. The starting concentrations of protofibrils and LMW A
, as
determined by AAA, were 19.2 and 15.5 µM, respectively.
Results are expressed as a percentage of the total number of counts
originally placed in each bag. Continuous functions were produced by
simple smoothing of the line segments joining the data points using the
smoothing algorithm resident in the graphing program Kaleidagraph
(version 3.0.8).
, protofibrils, and fibrils complicates the
analysis of precursor-product relationships. For example, although
unlikely, it is formally possible that protofibrils are reservoirs for
LMW A
, but do not themselves directly evolve into fibrils. To
address this issue, populations of protofibrils were isolated by SEC,
then their temporal change in size monitored by QLS. Initially,
protofibrils had an average hydrodynamic radius RH = 27.8 ± 1.8 nm (Fig. 3). This value
grew steadily with time, reaching a maximal value of 80.6 ± 14.4 nm at 236 h. For rigid rods, this value of RH
would correspond to lengths of the magnitude of 1 µm. Later, the
scattering intensity decreased, a phenomenon routinely observed as
large aggregates sediment and leave the illuminated portion of the
cuvette. After 263 h, the sealed tube was opened, the contents
gently homogenized by pipetting, and aliquots removed for EM and AAA.
EM revealed the presence of both fibrils and protofibrils with
morphologies similar to those seen in Fig. 1 (data not shown). The EM
findings were consistent with the changes in RH
observed by QLS, supporting the hypothesis that protofibrils are direct
precursors of fibrils.

View larger version (12K):
[in a new window]
Fig. 3.
Temporal change in protofibril size monitored
by QLS. Protofibrils were isolated by SEC and their average
hydrodynamic radii (RH) were periodically determined
using QLS during an 11-day incubation at room temperature. At each
monitoring time, multiple determinations were made, each of which is
presented in the figure. The total A
concentration in the experiment
shown was 17 µM.
-pleated sheets (38, 39). In six independent
experiments, protofibrils and LMWA
were isolated by SEC and their
ability to bind Congo red compared with that of fibrils. We have
observed that protofibril solutions at A
concentrations >20
µM readily form fibrils, thus in order to ensure that any
dye binding ascribed to protofibrils was not due to fibrils formed
de novo, A
concentrations were kept below 20 µM. In addition, the protofibrillar nature of each sample
was confirmed directly by electron microscopy. We found that LMW A
, even at concentrations as high as 70 µM, did not bind
Congo red, whereas both fibrils and protofibrils did, even at
concentrations as low as 2 µM (Fig.
4A). Protofibrils bound Congo red in a
concentration-dependent manner, however, variability in
this binding was observed, especially at low concentration (<5
µM). This effect is likely due to dissociation of
protofibrils into LMW A
(which does not bind the dye), a process whose rate may depend on protofibril length and thus could differ among
samples due to stochastic variations in the fibril length distributions. Little variability was displayed by fibrils, which also
consistently bound slightly higher amounts of dye than did equivalent
amounts of protofibrils.

View larger version (21K):
[in a new window]
Fig. 4.
Tinctorial properties of fibrils and
protofibrils. Fibrils, protofibrils, and LMW A
were treated
with Congo red and thioflavin T and the amounts bound determined by
absorption or fluorescence, respectively. A, Congo red
binding was performed in triplicate, on three different samples.
Results from a representative experiment are expressed as the average
concentration of Congo red bound (nM ± S.D.). In some
cases, error bars are not obvious because of their small
magnitude. Correlation coefficients (r2) for the
concentration dependence lines of fibrils and protofibrils were 0.993 and 0.997, respectively. B, thioflavin T binding was
measured and plotted in a similar manner. Results are expressed in
terms of average fluorescence intensity, F, measured in
arbitrary units (F ± S.D.). Fibril and protofibril
r2 values were 0.999 and 0.934, respectively.
, bound thioflavin T
(Fig. 4B). Interestingly, in two experiments, protofibrils bound more ThT than did equivalent amounts of fibrils (data not shown),
whereas the opposite was true in the other two experiments. Absolute
values of dye binding can differ depending on the protofibril or fibril
preparation. This can occur due to differences in the distribution of
polymer sizes, and to post-fibrillogenesis fibril-fibril interactions,
which cause equivalent amounts of A
to display different binding
activities. Nevertheless, the data show clearly that protofibrils bind
both Congo red and thioflavin T, a property of amyloid fibrils not
possessed by LMW A
. This suggests that protofibrils contain
significant amounts of
-sheet structure and must thus evolve
following significant conformational changes in LMW A
.
-sheet structure, however, the negative absolute value of the 200 nm maximum suggests that a significant level of random coil structure exists in the sample.
In fact, deconvolution of the spectrum showed 47%
-structure (
-sheet or
-turn), 40% random coil, and 13%
-helix.
Examination of numerous other protofibril samples has consistently
yielded percentages of
-content ranging from 45 to 50 (data not
shown). The
-content of protofibrils is quite similar to that of
fibrils (see day 31 data in Table I),
even though no fibrils were detected by EM in any of the protofibril
samples used for CD. The modest level of
-helix found in
protofibrils is interesting in light of the fact that during
fibrillogenesis of LMW A
, the peptide undergoes a conformational
transition from a predominately random coil structure to a
-sheet-rich form, during which a transitory
-helical component is
observed (Fig. 5B and Table I). In the case of protofibrils,
because CD is an averaging technique, it is not possible to say whether
the
-helix signal observed emanates from all protofibrils or whether
discrete subpopulations of protofibrils or of A
monomers or
oligomers exist which are significantly richer in this secondary
structure element. However, comparative analysis of the CD data from
fibrils, protofibrils, and LMW A
, does allow the conclusion to be
made that protofibrils are a relatively mature stage of the
fibrillogenesis process.

View larger version (20K):
[in a new window]
Fig. 5.
Secondary structure analysis of protofibrils
and LMW A
. CD spectroscopy was performed
on freshly isolated protofibrils (A) and LMW A
(B). Protofibril and LMW A
concentrations were 18.5 and
54 µM, respectively. In the case of LMW A
, spectra
were taken immediately upon isolation, then after 11, 20, 24, 27, and
31 days. Results are expressed as molar ellipticity [
] (deg
cm2 dmol
1). The data shown are representative
of those obtained in each of five independent experiments.
Temporal change in A
conformation during fibrillogenesis
fibrils were also assayed. As expected, fibrils significantly and
consistently produced decreases in reduced MTT levels (Fig. 6). Among
different experiments, the absolute levels of inhibition caused by
protofibrils and fibrils varied, however, in all cases, statistically
significant levels of inhibition were observed at A
concentrations
exceeding ~9 µM. The effect of LMW A
was then
compared with those of the fibrils and protofibrils. In two
experiments, LMW A
caused a slight but insignificant increase in
levels of reduced MTT (Fig. 6), while in a third experiment, a slight
but insignificant decrease was seen (data not shown). These results
indicate that protofibrils alter the normal physiology of cultured
neurons, whereas LMW A
does not.

View larger version (39K):
[in a new window]
Fig. 6.
Biological activity of protofibrils.
Primary rat cortical neurons were incubated for 2 h with fibrils,
protofibrils, LMW A
, or medium alone, MTT was added, and then the
cells were solubilized 3 h later. Data are expressed as average
percent inhibition of MTT reduction ± S.D. (n
8),
relative to cells treated with medium alone. Total A
concentrations
(µM) in each treatment group, determined by AAA, are
listed on the abscissa. The data shown are from a single
experiment, but are representative of a total of three independent
experiments in which protofibril, fibril, and LMW A
concentrations
ranged from 6 to 26 µM, 4 to 30 µM, and 6 to 44 µM, respectively. The concentration variation shown
for protofibrils was achieved by fractionation of the protofibril peak
as it eluted from the SEC column (see "Experimental Procedures").
Pre facto preparation of a protofibril dilution series is
difficult due to the rapid equilibria among protofibrils, LMW A
, and
fibrils, which effectively limits protofibril concentration to a
maximum of ~20 µM. Relative to medium alone, fibrils
and protofibrils both produced significant decreases in levels of
reduced MTT (*, p < 0.01), while LMW A
did
not.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
is archetypal. Through studies of A
fibrillogenesis, therefore, we hope not only to develop therapeutic
strategies for Alzheimer's disease, but to elucidate common features
of amyloid fibril assembly, thereby accelerating progress toward
treatment of other amyloidoses. In the studies reported here, our focus
was the assembly, structure, and biological activity of protofibrils,
important intermediates in the fibrillogenesis process (22, 26,
27).
, protofibrils, and fibrils suggested that
protofibrils were intermediates in the conversion of LMW A
into
fibrils. Here, we examined this question directly and found that
protofibrils were indeed in equilibrium with LMW A
and were capable
of forming fibrils. In our dialysis paradigm, the fact that we observed
neither complete conversion of protofibrils into fibrils, nor complete
protofibril dissociation into LMW A
(a range of 18-41% was
observed), demonstrates that competing rate constants for protofibril
dissociation and fibril formation must be of similar magnitude. The
kinetic description of this system is complicated by additional rate
constants for protofibril nucleation and elongation. Empirical evidence
also suggests that systematic variation in protofibril dissociation
rates may occur with protofibril length, further increasing the
complexity of this system. Independent of these issues, the most
straightforward interpretation of the data is that protofibrils are
precursors of fibrils and that fibrils, once formed, do not readily
dissociate into protofibrils or LMW A
. Irreversible protofibril
maturation into fibrils is consistent with the results of our
experiments in which temporal increases in average protofibril size
were observed by QLS and accompanied by electron microscopically
confirmed fibril formation. The same conclusion has been reached in AFM
studies of the temporal changes in A
polymer structure occurring
during fibrillogenesis (22, 27). Our data are also concordant with results of a number of studies showing that A
fibrils do not dissociate in the absence of strong chaotropic agents or solvents (28,
45, 46).
fibril transition comes from
studies designed to elucidate the structural relationships among LMW
A
, protofibrils, and fibrils. In these experiments, each species was
studied using dye binding and CD approaches. Because binding of Congo
red and thioflavin T is dependent on the presence of
-sheet
structure (47), the data show that protofibrils have significant
-sheet content. Whether statistically significant differences in dye
binding exist between protofibrils and fibrils is difficult to
determine due to variations in dye binding capacity of different fibril
preparations and to the confounding effects of light scattering by
different A
polymers (48). Interestingly, but not surprisingly, LMW
A
, even at concentrations up to 70 µM, showed no Congo
red or thioflavin T binding, indicating that the assays can
differentiate fibrillar and non-fibrillar A
. CD data were consistent
with the above observations. On average, both protofibrils and fibrils
contained substantial and equivalent levels (up to 50%) of
-structure (
-strand and
-turn), along with lesser amounts of
random coil (~40%) and
-helix (~10%). LMW A
, on the other
hand, was predominantly disordered. By these measurements, protofibrils
are similar to fibrils and are thus relatively advanced intermediates
in the fibrillogenesis process.
during fibril formation was that of a
transitory
-helical component. CD and QLS studies showed that LMW
A
lacked significant ordered structure. However, upon prolonged
incubation, a random coil
-sheet transition was observed, during
which the percentage of
-helix rose and fell. Other studies of
A
(1-40) fibrillogenesis at neutral pH also revealed a random coil
-sheet transition (49-51). However, to our knowledge, no transitory
-helical component has been described previously under conditions where helix-stabilizing solvents (fluorinated alcohols) were
not used. Our ability to observe this transition may result from the
use of LMW A
rather than A
lyophilizates which are simply
solvated and used directly. For example, we find that LMW A
(1-42)
has little regular
structure,2 whereas in other
studies of this peptide, even in solutions containing fluorinated
alcohols, CD spectra have consistently yielded a high content of
-sheet (49, 52). These contrasting observations suggest that the
starting materials used by others contained significant amounts of A
aggregates. The significance of the transitory
-helical component is
unclear. Because CD is a global averaging method, it is formally
possible that not all A
molecules conformationally transform through
this "
-helix" pathway. However, we feel it is most likely that
the conformational transition of A
from a predominately unstructured
monomer (or dimer) to an assembled
-sheet-rich fibril involves a
folding intermediate containing one or more
-helices which then
unfold and reform into
-strands. Interestingly, in the case of the
scrapie prion protein, a helix
strand folding pathway has, in fact,
been postulated to occur during the conversion of the cellular form of
the molecule (PrPC) into its scrapie form
(PrPSc) (53, 54). In addition, recent studies of a model 38 residue peptide,
t
(55, 56), have shown that a stable monomeric helical hairpin peptide can rearrange to form classical
-sheet-rich amyloid fibrils.3
and its assemblies. We have discussed above certain of
the conformational transitions in A
occurring during protofibril and
fibril formation. We find, as well, that maturation of protofibrils
into fibrils may involve subtle alterations in the structural
organization of the fibril. In particular, the "beaded"
substructure of protofibrils is less prominent in the fibrils. Harper
et al. (27) have reported a ~20 nm periodic structure in
A
(1-40) protofibrils studied by AFM. These protofibrils give rise
to fibrils in which this period doubles, as does fibril diameter.
However, fibrils also form which have diameters approximately equivalent to those of protofibrils and which have a much smoother appearance, a result of substantially less frequent axial
discontinuities (often <0.01 nm
1) (27). A granular
smooth transition has been reported by Seilheimer et al.
(57) during fibril formation by Met(O)-A
(1-42). In this study, the
authors noted the appearance of large globules and beaded complexes,
but these were larger (~30 nm) than those observed here. The
protofibril structures observed here may result from the assembly of
globular subunits. Small structures of this type have been observed in
fibrillogenesis studies of A
(1-40) and A
(1-42), both using AFM
(22, 27, 58) and EM (26, 59). In addition, recent cryoelectron
microscopic studies have revealed prominent inhomogeneities within
protofibrils, which in some samples appear to derive from the presence
of globular subunits.4 The
diameters of the globular assemblies reported here (3-6 nm) are
similar to those of ADDLs (58). In fact, this type of small globular
assembly may represent a structural unit from which protofibrils are
assembled (59). Geometric considerations suggest that as few as 5 or 6 A
molecules could constitute this structure. This size is consistent
with that of the "
-crystallite" suggested, on the basis of fiber
x-ray diffraction studies, to be a building block of A
fibrils (60).
A pentameric or hexameric building block has also been proposed by the
Murphy group (61). It should be noted, however, that depending on the
resolution of the visualization method, helices of appropriate pitch
can also appear as stacked arrays of globular units.
-mediated toxicity (23, 41-43). Changes in
MTT reduction may reflect alterations in endocytosis, exocytosis, or
cellular MTT reductase activity (43, 62, 63). The use of this type of
assay, in which effects can be evaluated within 30 min of treatment
(43), was critical for allowing a direct correlation between the
structures of A
assemblies and their biological activities. To
measure A
-induced cell death requires days of incubation (40),
during which protofibrils can be converted to fibrils. This makes
determination of the actual active moieties difficult. We found that
fibrils and protofibrils both produced highly significant,
concentration-dependent decreases in levels of reduced MTT
in cultures of rat cortical neurons, whereas no effects were observed
for LMW A
. Our prior studies of the kinetics of protofibril
formation, dissolution, and maturation support the conclusion that the
observed effects resulted from the direct interaction of protofibrils,
and not fibrils, with the cultured neurons. This conclusion is further
corroborated by studies demonstrating that protofibrils (prepared
identically to those used here) instantaneously alter the electrical
activity of cultured rat cortical neurons
(64).6 Whether the metabolic
changes mediated by A
are induced at the cell surface by interaction
with specific receptors (43, 62) or require internalization of
protofibrils or fibrils is currently unknown. However, our results show
clearly that whatever the mechanism, protofibrils and fibrils perturb
neuronal metabolism whereas LMW A
does not. The alteration in
neuronal MTT metabolism observed here may be an early indicator of a
process leading to neuronal dysfunction and subsequent cell death.
has been an area of active investigation
since the first demonstration that an A
peptide could kill cultured
neurons (65). Subsequent studies provided evidence that the A
molecule had to be fibrillar to be neurotoxic (66-68), and this
observation stimulated the development of strategies to inhibit fibril
formation and to dissolve preformed fibrils (17, 18). However, the work
reported here, and the recent observation of neurotoxicity of
non-fibrillar A
-derived diffusible ligands (58), suggest that the
notion that only fibrils are toxic must be revisited. For example, if
inhibition of fibril formation were to cause an accumulation of
protofibrils, A
-derived diffusible ligands, or other neurotoxic pre-
or non-fibrillar assemblies, this strategy clearly would not be of
value. To avoid this outcome, a better understanding of the assembly of
fibrils, and in particular, of their prefibrillar intermediates, must
be achieved. This will facilitate proper targeting and design of fibrillogenesis inhibitors.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Yuhui Xu for assistance with preparation of shadow casts, Dr. Tomas Ding for atomic force microscopy analysis, and Sara Vasquez for help in the preparation and maintenance of primary cultures. We acknowledge Drs. Dan Kirschner, David Howlett, Peter Lansbury, and John Maggio for critical comments and helpful discussions.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants 1P01 AG14366 (to D. B. T.), 1R01 NS38328 (to D. B. T.), and 1R01 AG12749 (to D. J. S.), through the generosity of the Foundation for Neurologic Diseases, and Amgen/MIT and Amgen/Brigham and Women's Hospital research collaboration agreements.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Center for Neurologic Diseases, Brigham & Women's Hospital, 77 Ave. Louis Pasteur (HIM756), Boston, MA 02115. Tel.: 617-525-5270; Fax: 617-525-5252; E-mail: teplow@cnd.bwh.harvard.edu.
2 D. M. Walsh and D. B. Teplow, unpublished data.
3 Y. Fezoui and D. B. Teplow, manuscript in preparation.
4 B. Bohrmann, D. M. Walsh, and D. B. Teplow, unpublished results.
5 D. M. Walsh, D. M. Hartley, D. J. Selkoe, and D. B. Teplow, unpublished data.
6 D. M. Hartley, Walsh, D. M., Ye, C. P., Diehl, T. S., Vassilev, P. M., Teplow, D. B., and Selkoe, D. J. submitted for publication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
AD, Alzheimer's
disease;
A
, amyloid
-protein;
APP, amyloid
-protein
precursor;
SEC, size exclusion chromatography;
LMW, low molecular
weight;
AAA, amino acid analysis;
QLS, quasielastic light scattering
spectroscopy;
ThT, thioflavin T;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
AFM, atomic force microscopy.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Alzheimer, A. (1906) Neurol. Centr. 23, 1129-1136 |
| 2. | Teplow, D. B. (1998) Amyloid: Int. J. Exp. Clin. Invest. 5, 121-142 |
| 3. | Chartier-Harlin, M.-C., Crawford, F., and Houlden, H. (1991) Nature 353, 844-846[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M., and Hardy, J. (1991) Nature 349, 704-706[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Mullan, M., Crawford, F., Houlden, H., Axelman, K., Lilius, L., Winblad, B., and Lannfelt, L. (1992) Nat. Genet. 1, 345-347[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Eckman, C. B.,
Mehta, N. D.,
Crook, R.,
Perez-Tur, J.,
Prihar, G.,
Pfeiffer, E.,
Graff-Radford, N.,
Hinder, P.,
Yager, D.,
Zenk, B.,
Refolo, L. M.,
Prada, C. M.,
Younkin, S. G.,
Hutton, M.,
and Hardy, J.
(1997)
Human Mol. Genet.
6,
2087-2089 |
| 7. |
Levy-Lahad, E.,
Wijsman, E. M.,
Nemens, E.,
Anderson, L.,
Goddard, K. A. B.,
Weber, J. L.,
Bird, T. D.,
and Schellenberg, G. D.
(1995)
Science
269,
970-973 |
| 8. |
Levy-Lahad, E.,
Wasco, W.,
Poorkaj, P.,
Romano, D. M.,
Oshima, J.,
Pettingell, W. H., Yu, C. E.,
Jondro, P. D.,
Schmidt, S. D.,
Wang, K.,
Crowley, A. C.,
Fu, Y. H.,
Guenette, S. Y.,
Galas, D.,
Nemens, E.,
Wijsman, E. M.,
Bird, T. D.,
Schellenberg, G. D.,
and Tanzi, R. E.
(1995)
Science
269,
973-977 |
| 9. | Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A. R., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommen, J. M., and St. George-Hyslop, P. H. (1995) Nature 375, 754-760[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Selkoe, D. J.
(1997)
Science
275,
630-631 |
| 11. | Hardy, J. (1997) Trends Neurosci. 20, 154-159[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Corder, E. H.,
Saunders, A. M.,
Strittmatter, W. J.,
Schmechel, D. E.,
Gaskell, P. C.,
Small, G. W.,
Roses, A. D.,
Haines, J. L.,
and Pericak-Vance, M. A.
(1993)
Science
261,
921-923 |
| 13. | Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L., Horvath, S. M., Go, R. C., Perry, R., Watson, B., Jr., Bassett, S. S., McInnis, M. G., Albert, M. S., Hyman, B. T., and Tanzi, R. E. (1998) Nat. Genet. 19, 357-360[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Mattson, M. P.
(1997)
Physiol. Rev.
77,
1081-1132 |
| 15. | Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M. L., and Yankner, B. A. (1998) Nature Med. 4, 827-831[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | McKee, A. C., Kowall, N. W., Schumacher, J. S., and Beal, M. F. (1998) Amyloid: Int. J. Exp. Clin. Invest. 5, 1-9 |
| 17. | Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castano, E. M., and Frangione, B. (1998) Nature Med. 4, 822-826[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Schenk, D. B., Rydel, R. E., May, P., Little, S., Panetta, J., Lieberburg, I., and Sinha, S. (1995) J. Med. Chem. 38, 4141-4154[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Ghanta, J.,
Shen, C. L.,
Kiessling, L. L.,
and Murphy, R. M.
(1996)
J. Biol. Chem.
271,
29525-29528 |
| 20. |
Tjernberg, L. O.,
Naslund, J.,
Lindqvist, F.,
Johansson, J.,
Karlstrom, A. R.,
Thyberg, J.,
Terenius, L.,
and Nordstedt, C.
(1996)
J. Biol. Chem.
271,
8545-8548 |
| 21. | Jarrett, J. T., Berger, E. P., and Lansbury, P. T., Jr. (1993) Biochemistry 32, 4693-4697[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T. (1997) Chem. Biol. 4, 119-125 |